In vitro synergistic effect of moxifloxacin and amphotericin B combination against candida strains;Moksi̇floksasi̇n ve amfoteri̇si̇n b kombi̇nasyonunun Candida türleri̇ üzeri̇ne i̇n vi̇tro si̇nerji̇sti̇k etki̇si̇

Mikrobiyoloji Bulteni

Volumn 44, Issue 1, 2010, Pages 65-70

  Yalçin, Burçe ^a   Kalkanci, Ayşe ^a   Gürellk, Feryal ^a   Fidan, Işil ^a   Kuştimur, Semra ^a   Özdek, Şengül ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Amfotericin B; Antifungal; Checkerboard; FIC; Moxifloxacin; Synergy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ARTICLE; CANDIDA; CANDIDIASIS; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

AMPHOTERICIN B; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; AZA COMPOUNDS; CANDIDA; CANDIDIASIS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLINES;

EID: 77749307647     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008; 8: 574-81.
2. Shen LL, Baranowski J, Fostel J, Montgomery DA, Lartey PA. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother 1992; 36: 2778-84.
3. Polak A. In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinotone. Mycoses 1990; 33: 173-8.
4. rd ed. CLSI, Wayne, Pennsylvania.
5. Isenberg HD (ed). Synergism testing: broth microdilution checkerboard and broth macrodilution methods, pp: 5.18.1. In: Clinical Microbiology Procedures Handbook. 1992, Vol I. American Society for Microbiology, Washington, DC.
6. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
7. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they? Antimicrob Chemother 2004; 54: 854-69.
8. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother 2005; 49: 3544-5.
9. Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Akgun Y. Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrob Agents Chemother 2009; 53: 788-90.
10. Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother 1995; 39: 1517-21.
11. Sugar AM, Liu XP, Chen RJ. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother 1997; 41: 2518-21.
12. Sasaki E, Maesaki S, Miyazaki Y, et al. Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans. J Infect Chemother 2000; 6: 151-4.
13. Ozdek SC, Miller D, Flynn PM, Flynn HW. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm 2006; 14: 347-51.
14. Vitale RG, Afeltra J, de Hoog GS, Rijs AJ, Verweij PE. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother 2003; 51: 1297-300.
15. Sugar AM, Liu XP. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother 2000; 44: 2004-6.
16. Stergiopoulou T, Meletiadis J, Sein T, et al. Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2196-204.
17. Stergiopoulou T, Meletiadis J, Sein T, et al. Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother 2009; 63: 343-8.
18. Gruger T, Morier C, Schnitzler N, et al. Influence of fluoroquinolones on phagocytosis and killing of Candida albicans by human polymorphonuclear neutrophils. Med Mycol 2008; 46: 675-84.
19. Shalit I, Horev-Azaria L, Fabian I, et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 2002; 46: 2442-49.
20. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007; 45: 569-87.